Semax 0.1% nasal drops 3 ml

Intellectual-memory disorders due to vascular lesions of the brain; conditions following traumatic brain injury, neurosurgical operations, and anesthesia; dyscirculatory encephalopathy; transient disturbances of cerebral circulation (TIA); as well as neurotic disorders of various origins, including those following ionizing radiation; recovery period after stroke. To enhance the adaptive capabilities of the human body in extreme situations; prevention of mental fatigue during monotonous operator activities in the most intense work periods under stress conditions.
In ophthalmology, Semax is used for optic nerve atrophies and neuritis of inflammatory, toxic-allergic etiology.
In pediatrics: as a nootropic agent for children aged 7 years and older in the treatment of minimal brain dysfunctions (including ADHD - Attention Deficit Hyperactivity Disorder).

Semax is administered intranasally using a bottle sealed with a plastic screw cap or a dropper cap.
If the bottle is sealed with a plastic screw cap, remove the cap upon first use and replace it with the provided dropper with a cap.
Draw the medication into the dropper. Slightly tilt your head to the side and dispense the required number of drops onto the mucous membrane of the nasal passage. If the bottle is sealed with a dropper cap, carefully cut the tip of the dropper, securely close the dropper with the cap. Before use, turn the bottle upside down to fill the dropper completely with the liquid. Remove the cap and dispense the required number of drops onto the mucous membrane of the nasal passage.
Store the bottle tightly closed with the dropper cap, or with the plastic screw cap, or with the dropper cap.
One drop of the standard solution contains 50 mcg of the active substance. Using the dropper, administer no more than 2-3 drops into each nasal passage. If a higher dosage is needed, administration can be done in several doses with intervals of 10-15 minutes.
For intellectual-mnestic disorders due to vascular lesions of the brain, discirculatory encephalopathy, and transient disturbances of cerebral circulation, the single dose is 200 - 2000 mcg (based on 3-30 mcg/kg).
The daily dose is 800-8000 mcg (based on 7-70 mcg/kg).
The medication is prescribed at 2-3 drops in each nasal passage 4 times a day for 10 -14 days; if necessary, the treatment course can be repeated.
After traumatic brain injury, neurosurgical operations, and anesthesia, the single dose is 1400 - 3500 mcg (40-50 mcg/kg) 3 times a day for 3 - 5 days. If necessary, the treatment course can be extended to 14 days.
To enhance the adaptive capabilities of the human body and to prevent mental fatigue, administer 2-3 drops in each nasal passage 2-3 times in the first half of the day for 3-5 days. The daily dose is 400-900 mcg/day. If necessary, the treatment course can be repeated.
In cases of optic nerve diseases, the medication is instilled at 2-3 drops in each nasal passage 2-3 times a day. The daily dose is 600-900 mcg/day. The treatment course lasts 7-10 days. Additionally, the medication can be administered via endonasal electrophoresis. The medication is introduced from the anode. Current strength is 1 mA, duration of exposure is 8 -12-15 minutes.
The daily dose is 400-600 mcg/day. The treatment course lasts 7-10 days.
In pediatrics:
For children aged 7 years and older. In cases of minimal brain dysfunctions: 1-2 drops in each nasal passage (based on 5-6 mcg/kg) 2 times a day (in the morning and during the day). The daily dose is 200-400 mcg/day. The treatment course lasts 30 days.

Semax, calculated as 100% substance - 1 g; methylparaben (Nipagin) - 1 g; purified water to 1 l.

Colorless transparent liquid.

Increased sensitivity to the components of the drug. Children under 7 years old. In ophthalmological and neurosurgical practice, children under 18 years old. Pregnancy, lactation period, acute mental conditions, disorders accompanied by anxiety, history of seizures.
Use in children under 18 years old in ophthalmological and neurosurgical practice is contraindicated. Clinical studies have not been conducted.
Pregnancy and lactation:
Contraindicated. Clinical studies have not been conducted.

Prolonged use may cause mild irritation of the nasal mucosa.

No overdose phenomena of the drug have been identified to date, even with a significant increase in the single dose.

Pharmaceutical. Based on the chemical structure of the drug, the presence of chemically incompatible combinations is not anticipated: the drug is rapidly destroyed and does not enter the gastrointestinal tract.
Pharmacokinetic. Considering the chemical structure of the drug (heptapeptide - a synthetic analog of adrenocorticotropic hormone, completely devoid of hormonal activity), the rapid absorption and rate of entry into the bloodstream, as well as the intranasal route of administration, the influence of other drugs on the pharmacokinetic parameters of Semax nasal drops 0.1% is not anticipated. Given the method of administration of Semax nasal drops 0.1% (intranasal), the introduction of agents with local vasoconstrictive action during their intranasal administration is undesirable.

Semax Nasal Drops 0.1% - an original synthetic peptide preparation, which is an analogue of the fragment of adrenocorticotropic hormone (ACTH4-10) (methionyl-glutamyl-histidyl-phenylalany-prolyl-glycyl-proline), completely devoid of hormonal activity. All amino acids are in the L-form.

Semax Nasal Drops 0.1% has a unique mechanism of neuro-specific action on the central nervous system (CNS). Semax Nasal Drops 0.1% is a synthetic analogue of corticotropin, possessing nootropic properties and completely devoid of hormonal activity. The preparation affects processes related to memory formation and learning. Semax Nasal Drops 0.1% enhances attention during learning and information analysis, improves the consolidation of memory traces in patients after neurosurgical interventions, traumatic brain injury, and those suffering from cerebrovascular diseases, including dyscirculatory encephalopathy; improves the body's adaptation to hypoxia, cerebral ischemia, anesthesia, and other damaging effects. The preparation is practically non-toxic with single and prolonged administration. It does not exhibit allergic, embryotoxic, teratogenic, or mutagenic properties. It does not have a local irritating effect.

It is absorbed through the mucous membrane of the nasal cavity, with 60-70% of the active substance being bioavailable. Semax nasal drops 0.1% are rapidly distributed to all organs and tissues, penetrating the blood-brain barrier. Upon entering the bloodstream, Semax nasal drops 0.1% undergoes relatively rapid degradation and is excreted from the body via urine.